Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
Multiple Sclerosis News Today4d
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
PMLiVE5d
Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS
Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy ...
Monthly Prescribing Reference8d
Tolebrutinib Gets Breakthrough Tx Status for Non-Relapsing Secondary Progressive MS
The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.
EuropaWire8d
Tolebrutinib Receives FDA Breakthrough Therapy Designation for Progressive Multiple Sclerosis
The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary ...
EuropaWire8d
Tag Archives: Progressive Multiple Sclerosis
(IN BRIEF) The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS), following positive results ...
The Pharma Letter8d
FDA status for Sanofi’s tolebrutinib in non-relapsing secondary progressive MS
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
PharmiWeb8d
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Sanofi's Tolebrutinib Gets FDA Breakthrough Therapy Designation For NrSPMS
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
Sanofi: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-r ...
Pharmaceutical Technology8d
Risk adjusted net present value: What is the current valuation of Sanofi’s Tolebrutinib?
Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Secondary Progressive Multiple Sclerosis (SPMS).